NEW YORK and CAMBRIDGE, Mass., Nov. 1, 2017 — BlueRock Therapeutics, a company developing cell-based therapies designed to alter the course of degenerative disease, today announced that its president and chief executive officer, Emile Nuwaysir, Ph.D., has been appointed to The Alliance for Regenerative Medicine (ARM) 2018 Executive Committee and Board of Directors.
“With a mission to facilitate access to life-giving advances in regenerative medicine worldwide, ARM represents a leading organization in our field and one in which I’m proud to play a role,” said Dr. Nuwaysir. “I am joining a board of accomplished leaders and scientists who share a vision to advance the entire regenerative medicine community by working to increase public understanding of the field and promote legislative, regulatory and reimbursement initiatives to create a clear path to deliver disease altering treatments for patients.”
The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming year. Each group is held to an annual reelection or rotation process, with nominations and approval by the ARM membership and current Board.
About BlueRock Therapeutics
Driven by a vision to liberate patients from the burden of degenerative disease, BlueRock Therapeutics is ushering in a new era of cell-based medicine that repairs the body when it cannot repair itself. Founded in 2016 through one of the largest Series A financings in biotech history, BlueRock and its team of preeminent scientists are pioneering cell therapies that replace dead, damaged or dysfunctional cells to restore critical natural functions in the body. Using an approach that can be applied to multiple diseases with great unmet need, BlueRock is initially targeting severe brain and heart conditions, with the goal of altering the course of disease and drastically improving quality of life. BlueRock’s culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit www.bluerocktx.com.
Media Contact
Jessica Dyas
Canale Communications
jessica@canalecomm.com
619-849-5385
